The results revealed that the expression levels of CFP in kidney cancer, and lymphoma were higher compared with the normal tissues, while in bladder cancer, brain and CNS cancer, breast cancer, colorectal cancer, leukemia, liver cancer, lung cancer, myeloma, ovarian cancer and sarcoma decreased significantly (Figure 1A). This evidence concerns the gene CFP and plasma cell myeloma.